<DOC>
	<DOCNO>NCT01765257</DOCNO>
	<brief_summary>Among psychiatric symptom observe premotor phase Parkinson 's disease ( PD ) and/or `` de novo '' patient , apathy relatively frequent ( estimate 23 % ) . However , neuropathological base apathy still unknown . However , recent data suggest apathy could link specific dopaminergic denervation ventral striatum . Rasagiline increase bioavailability striatal endogenous dopamine block MAO-B . Some recent data suggest rasagiline could effective improve apathy Parkinson 's disease . The primary outcome demonstrate significant reduction apathy use Lille apathy rating scale ( LARS ) drug naive patient early diagnose Parkinson 's disease , use treatment rasagiline .</brief_summary>
	<brief_title>Evaluation Efficacy Rasagiline Apathy Drug-naïve Patients With Parkinson 's Disease Multi-center Study</brief_title>
	<detailed_description>Study design : Randomized , double-blind , rasagiline ( 1 mg ) v placebo study . Parallel group ( randomization 1/1 ) . Duration 3 month 16 recruit center France Population : 50 drug-naïve patient Parkinson 's disease , apathy . 2 group : 25 patient placebo 25 patient rasagiline . 3 visit - Visit 1 : inclusion / randomisation/ first study medication dispensation - Visit 2 ( 1.5 month V1 ) : first evaluation second study medication dispensation . - Visit 3 ( 3 month V1 , final visit ) : second evaluation</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Rasagiline</mesh_term>
	<criteria>Drugnaïve patient Parkinson 's disease ( UKPDBB criterion ) No dementia ( Mattis dementia rating scale &gt; 130 ; Mini Mental Sate Examination ≥26 ) No depression ( MADRS &lt; 15 ) Criteria apathy Robert et al ( 2009 ) At least mild apathy ( ≥21 Lille Apathy Rating Scale ) Age : 3570 Affiliation social security Agreement patient Any antiparkinsonian treatment ( L.dopa , dopamine agonist , MAOBI , amantadine , anticholinergic ) . Patients treat dopamine agonist stop 3 month inclusion include . Ongoing severe psychiatric somatic disease Others treatment : antipsychotic antidepressant anxiolytic ( exclusion treatment stable month inclusion ) psychostimulants ( methylphenidate , adrafinil , modafinil , deanol , vitamin C , sulbutiamine , glutamic acid , aspartic acid ) contraindication accord SmPC patient guardianship Women without efficient contraception Person participate study</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Drug-naïve patient Parkinson 's disease</keyword>
	<keyword>Apathy</keyword>
	<keyword>Rasagiline</keyword>
</DOC>